key: cord-0331251-uv93wb3b authors: Gondal, Mahnoor Naseer; Chaudhary, Safee Ullah title: Navigating Multi-scale Cancer Systems Biology towards Model-driven Personalized Therapeutics date: 2021-05-17 journal: bioRxiv DOI: 10.1101/2021.05.17.444410 sha: e28c1ac94ac1f518c396bf5525d18b94d87ce581 doc_id: 331251 cord_uid: uv93wb3b Rapid advancements in high-throughput omics technologies and experimental protocols have led to the generation of vast amounts of biomolecular data on cancer that now populates several online databases and resources. Cancer systems biology models built on top of this data have the potential to provide specific insights into complex multifactorial aberrations underpinning tumor initiation, development, and metastasis. Furthermore, the annotation of these single- or multi-scale models with patient data can additionally assist in designing personalized therapeutic interventions as well as aid in clinical decision-making. Here, we have systematically reviewed the emergence and evolution of (i) repositories with scale-specific and multiscale biomolecular cancer data, (ii) systems biology models developed using this data, (iii) associated simulation software for development of personalized cancer therapeutics, and (iv) translational attempts to pipeline multi-scale panomics data for data-driven in silico clinical oncology. The review concludes by highlighting that the absence of a generic, zero-code, panomics-based multi-scale modeling pipeline and associated software framework, impedes the development and seamless deployment of personalized in silico multi-scale models in clinical settings. In 1971, President Richard Nixon declared his euphemistic "war on cancer" through the promulgation of the National Cancer Act (1-4). Five decades later, with billions spent on cancer research and development, a definitive and affordable treatment for the disease still evades humankind (5) . Numerous "breakthrough" treatments have gone on to exhibit adverse side effects (6, 7) that lower patients' quality of life (QoL) or have reported degrading efficacies(8). At the heart of this problem lies our limited understanding of the bewildering multifactorial biomolecular complexity as well as patient-centricity of cancer. Recent advances in biomolecular cancer research have helped factored the system-level oncological manifestations into mutations across genetic, transcriptomic, proteomic, and metabolomic scales (9-12) that also act in concert (13, 14) . Crosstalk between multiscale pathways comprising of these oncogenic mutations can further exacerbate the etiology of the disease (10, [15] [16] [17] . The combination of mutational diversity and interplay between the constituent pathways adds genetic heterogeneity and phenotypic plasticity in cancer cells (18) (19) (20) . Hanahan and Weinburg (21, 22) summarized this heterogeneity and plasticity into "Hallmarks of Cancer" -a set of progressively acquired traits during the development of cancer. Experimental techniques such as high throughput next-generation sequencing and mass spectrometry-based proteomics are now providing specific spatiotemporal cues on patientspecific biomolecular aberrations involved in cancer development and growth. The voluminous high-throughput patient data coupled with the remarkable complexity of the disease has also given impetus to data integrative in silico cancer modeling and therapeutic evaluation approaches (23) . Specifically, scale-specific molecular insights into key regulators underpinning each hallmark of cancers are now helping unravel the complex dynamics of the disease (24) besides creating avenues for personalized therapeutics (25, 26) . In this review, we will evaluate the emergence, evolution, and integration of multiscale cancer data towards building coherent and biologically plausible in silico models and their integrative analysis for employment in personalized cancer treatment in clinical settings. Rapid advancements in molecular biology research, particularly in high-throughput genomics (27), transcriptomics (28), and proteomics (29) have resulted in the generation of big data on spatiotemporal measurements of scale-specific biomolecules ( Figure 1A ) in physiological as well as pathological contexts (30,31). This vast and complex spatiotemporal data is expected to exceed 40 exabytes by 2025 (32), and is currently populating several online databases and repositories. These databases can be broadly categorized into seven salient database sub-types: biomolecules (33-35), pathways (36-38), networks (39-41), environment (42,43), cell lines (44-47), histopathological images (48-50), and mutations, and drug (51-56) databases, which are discussed below. Biomolecular and clinical data generated from large-scale omics approaches for cancer research can be divided into four sub-categories: (i) genome, (ii) transcriptome, (iii) proteome, and (iv) metabolome (57) . The foremost endeavor to collect and organize large-scale genomics data into coherent and accessible repositories led to the establishment of GenBank in 1986(58) ( Figure 1B, Supplementary Table 1 ). This open-access resource now forms one of the largest and most comprehensive public databases for nucleotide sequences from large-scale sequencing projects comprising over 300,000 species (59) . In a salient study employing GenBank, Diez et al. (60) screened breast and ovarian cancer families with mutations in BRCA1 and BRCA2 genes. Medrek et al. (61) employed microarray profile sets from GenBank to analyze gene levels for CD163 and CD68 in different breast cancer patient groups. To date, GenBank remains the largest and most comprehensive nucleotide database; however, its data heterogeneity poses a significant challenge in its employment in the development of personalized cancer therapeutics. Towards an improved data stratification and retrieval of genome-scale data, in 2002, Hubbard et al. (62) launched the Ensemble genome database. Ensemble provides a comprehensive resource for human genome sequences capable of automatic annotation and organization of large-scale sequencing data. Amongst various genome-wide studies utilizing Ensemble, Easton et al. (63) employed the database to identify novel breast cancer susceptibility loci. (ii) Transcriptome-scale Databases: Although gene-level information can facilitate the development of personalized cancer models, however, gene expression varies from cell to cell. As a result, different cancer patients have divergent genetic signatures and transcript-level gene expression (64) . Therefore, high-throughput transcriptomic data has the potential to provide valuable insights into the transcriptomic complexity in cancer cells and can be useful in investigating cell state, physiology, and relevant biological events (65, 66) (Figure 1B, Supplementary Table 1) . Towards developing a transcript information resource, in 2000, Edgar et al. (35, 67) launched the Gene Expression Omnibus (GEO) initiative. GEO acts as a tertiary resource providing coherent high throughput transcriptomic and functional genomics data. The platform now hosts over 3800 genomic datasets and is expanding exponentially and was employed by Chakraborty et al. (68) to annotate chemo-resistant cell line models which helped investigate chemoresistance and glycolysis in ovarian cancers. Furthermore, patient-specificity (13, 14) and mutational diversity (23) in cancer manifests across spatiotemporal scales. Hence, the availability of patient-specific data for each type of cancer has the potential to furnish valuable insights into the biomolecular foundation of the disease. In an attempt to provide cancer type-specific mutation data, Wellcome Trust's Sanger Institute (69) (71) characterized the genome of lung adenocarcinomas. The curation of patient-specific gene and protein expression data then led to the development of The Cancer Genome Atlas (TCGA) (72) . TCGA also captures the copy number variations and DNA methylation profiles for different cancer subtypes. TCGA's potential (53,73) is well exhibited by Leiserson et al.'s (74) investigation that helped identify combinations of rare somatic mutations across pathways and protein complexes. Davis et al. (75) further evaluated HPP towards identifying the complex protein machinery involved in cancer cell fate outcomes (101) (102) (103) (104) (105) (106) . Amongst the foremost attempts, in 2001, Sebastian et al. (107) employed the HPP platform to deduce the complex regulatory region of the human CYP19 gene ('armatose'), one of the contributors to breast cancer regulation. HPP project was later segmented into "biology and disease-oriented HPP" (B/D HPP) (108) and chromosome-centric HPP (C-HPP) (109) . Gupta et al. (110) carried out an extensive analysis of existing experimental and bioinformatics databases to annotate and decipher proteins associated with glioma on chromosome 12, while, Wang et al. (111) performed a qualitative and quantitative assessment of human chromosome 20 genes in cancer tissue and cells using C-HPP resources. (iv) Metabolome-scale Databases: Metabolic reprogramming is one of the earliest manifestations during tumorigenesis (112) and, therefore, potentiates identification of biomarkers involved in cancer onset, its prognosis as well as treatment. Large-scale efforts to collect metabolomics data led to the development of several online databases (113) (114) (115) (114) . HMDB contains organism-specific information on metabolites across various biospecimens and their accompanying environments. It is now the world's largest metabolomics database with around 114,100 metabolites that have been characterized and annotated. HMDB was employed by Sugimoto et al. (118) to identify environmental compounds specific to oral, breast, and pancreatic cancer profiles, while Agren et al. (119) constructed metabolic network models for 69 human cells and 16 cancer types. Although HMDB supports data deposition and dissemination, however, integrated exploratory analysis is not available. The Metabolomics Workbench (115) , reported in 2016, provides information on metabolomics metadata and experimental data across species, along with an integrated set of exploratory analysis tools. The platform also acts as a resource to integrate, deposit, track, analyze, as well as disseminate large-scale heterogeneous metabolomics data from a variety of studies. In a case study built using this platform, Hattori et al. (120) studied cancer progression by metabolic reprogramming in myeloid leukaemia, whereas, Playdon (121) investigated dietary biomarkers in breast cancer etiology. Investigations restricted to single specific biomolecular scales have limited translational potential as cancer dysregulation is driven by tightly coupled biomolecular pathways constituted by biomolecules from a variety of spatiotemporal scales (discussed above). Such biomolecular pathways represent organized cascades of interactions integrating different spatiotemporal scales towards reaching specific phenotypic cell fate outcomes. Numerous scale-specific and multi-omics biomolecular pathway databases now exist to help retrieve, store and analyze existing pathway information towards understanding cellular communication in light of complex cancer regulation (38, 122, 123) . One of the earliest attempts at integrating genomics data for pathway construction was in 1995, with the establishment of the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (122) (Figure 1C , Supplementary Table 2) . Over time, KEGG has significantly expanded to include high-throughput multi-omics data (124) . As a result, the resource is divided into fifteen sub-groups including KEGG Genome (for genome-level pathways), KEGG Compound (for small molecules level pathways), KEGG Gene (for gene and protein pathways), KEGG Reaction (for biochemical reaction and metabolic pathways), etc. Li et al. (125) used the KEGG database to perform pathway enrichment analysis for predicting the function of circular RNA (circRNA) dysregulation in cancer, while Feng et al. (126) identified genes associated with poor prognosis in ovarian cancer. To furnish information on pathways limited to geneprotein and protein-protein interactions for high-throughput functional analysis studies, PANTHER (protein annotation through evolutionary relationship) database was established in 2010 (38,123). PANTHER hosts information on ontological gene and protein-protein interaction pathways by leveraging GenBank and Human Gene Mutation Database (HGMD) (127), etc. Turcan et al. (128) employed PANTHER to perform network pathway enrichment for biological processes in differentially expressed genes to investigate IDHI mutations in glioma hypermethylation phenotype. In order to store metabolic pathway information in a cell, Karp et al. (129) developed MetaCyc, a comprehensive reference database of metabolic pathways. MetaCyc is currently available as a web-based resource with metabolic pathway information which can be employed to investigate metabolic reengineering in cancers, carry out biochemistry-based studies, and explore cancer cell metabolism, etc. Tang and Aittokalli (130) demonstrated the utility of MetaCyc database by annotating a human metabolic network to evaluate multi-target cancer treatments. The regulatory complexity of cancer is compounded by the cross-talk between multi-scale biomolecular pathways resulting in the formation of interaction networks ( Figure 1D , Supplementary Table 3 ). One of the earliest biomolecular network databases, the Biomolecular Interaction Network Database (BIND) (131) was established in 2001, with an aim to organize biomolecular interactions between genes, transcripts, proteins, metabolites, as well as small molecules. Chen et al. (132) employed BIND to construct a biological interaction network (BIN) towards investigating tyrosine kinase regulation in breast cancer development. Although BIND provides a comprehensive resource of predefined interacting pathways, however, it does not contain 'indirect' interaction information. In contrast, the Molecular INTeraction database (MINT) (41), developed in 2002, curates existing literature to develop networks with both direct as well as indirect interactions from large-scale projects with information from genes, transcripts, proteins, promoter regions, etc. MINT can store data on "functional" interaction as well such as enzymatic properties and modifications present in a biomolecular regulatory network. The database was employed by Sun et al. (133) to construct a human interactome network to evaluate cancer patients' interactome, whereas, Vinayagam et al. (134) constructed an HIV (human immunodeficiency virus) network that helped identify novel cancer genes across genomic datasets. The Database of Interacting Proteins (DIP) (135) was developed to mine existing literature and experimental studies on biomolecules and their pathways to construct interacting protein networks. Numerous studies on cancer research have been reported using DIP (136) (137) (138) . Goh et al. (136) constructed a protein-protein interaction network for investigating liver cancer using network information from DIP while Zhao et al. (137) identified microRNA-regulated autophagy pathways in plants. To further consolidate and integrate protein interaction data across pathways as well as organisms, the Search Tool for the Retrieval of Interacting Genes/Proteins -STRING database was developed in 2005 (139) . STRING provides a comprehensive text-mining and computational prediction platform which is accessible through an intuitive web interface (140) . STRING database also provides interaction weights for edges between biomolecules to show an estimated likelihood for each interaction in the network (140) . Mlecnik et al. (141) employed the STRING database to study T-cells homing factors in colorectal cancer. Later, Bindea et al. (142) assembled a gene-gene correlation network to investigate natural immunity to cancer in humans. Each pathway within a biomolecular network requires input cues from the extracellular environment for onward downstream signal transduction (143) (144) (145) . In the case of cancer, the biomolecular milieu constituting the tumor microenvironment (TME) acts as a niche for tumor development, metastasis, as well as therapy response (146) ( Figure 1E , Supplementary Table 4 ). Efforts to curate information from the environmental factors such as metabolites, matrisome, and other environmental compounds led to the development of MatrixDB (42) in 2011, which curated matrix-based information on interactions between extracellular proteins and polysaccharides. MatrixDB additionally links databases with information on genes encoding extracellular proteins such as Human Protein Atlas (147) and UniGene (148) as well as host transcripts information. Celik et al. (149) employed MatrixDB data to evaluate Epithelialmesenchymal transition (EMT) inducers in the environment in nine ovarian cancer datasets. With an aim to host studies on extracellular matrix (ECM) proteins from normal as well as diseaseinflicted tissue samples, MatrisomeDB (43) was established in 2020. The database contains 17 studies on 15 physiologically healthy murine and human tissue, and 6 cancer types from different stages (including breast cancers, colon cancers, ovarian cancers, lung cancers, and melanomas) along with other diseases. Levi-Galibov et al. (150) employed the MatrisomeDB to investigate the progression of chronic intestinal inflammation to colon cancer. In vitro cell lines derived from cancer patients have become an essential tool for clinical and translational research (151) . These cell lines are defined based on gene expression profiles and morphological features which have been cataloged in various databases such as the Cancer Cell Line Encyclopedia (CCLE) (46) ( Figure 1F , Supplementary (156) , and Massachusetts General Hospital (MGH) (157) and provides a platform for pharmacological and genomic analysis. Additionally, histopathological image datasets derived from the microscopic examination of tumor biopsy samples furnish information on cellular structure, function, chemistry, morphology, etc. Numerous histopathological image-based databases have been developed to store, manage and retrieve such information ( Figure 1G , Supplementary Table 6) . Amongst these databases, The Cancer Imaging Archive (TCIA) (48), reported in 2013, provides a multi-component architecture with various types of images including region-specific (e.g., Breast), cancer-type specific (e.g., TCGA-GBM, TCGA-BRCA), radiology, and anatomy images (e.g., Prostate-MRI). The cancer image collection in TCIA is captured using a variety of modalities including radiation treatment, X-ray, mammography, and computed tomography (CT), etc (158) . Zhu et al. (159) exhibited the value of TCIA by predicting the risk for breast cancer recurrence, while Sun et al. (160) employed image data to perform a cohort study to validate a radiomics-based biomarker in cancer patients. In 2013, Image data from TCIA was integrated with The Cancer Digital Slide Archive (CDSA) (49) which hosts imaging and histopathological data and provides more than 20,00 images from 22 different cancers. The integrated datasets in CDSA demonstrate the clinical association of genomic data with pathology imaging. The whole-slide images of individual patients are also reported in CDSA, thereby linking tumor morphology with the patient's genomic and clinical data. Khosravi et al. (161) performed a deep convolution study, using CDSA, to distinguish heterogeneous digital pathology images across different types of cancers. To associate a relationship between a patient's genetic information and histology images Genotype-Tissue Expression (GTEx) (50) was reported in 2014. The GTEx project was created from datasets from 1000 patients containing tissue-specific information on gene expression and regulation. Pharmacological investigations have elucidated the mechanism and efficacies of numerous cancer drugs, in clinical and preclinical studies (162, 163) . Databases with drug-target information can be employed in precision oncology towards designing efficacious patient-centric therapeutic strategies ( Figure 1H , Supplementary Table 7) . Such databases include DrugBank (164) , established in 2006, which contains information from over 4100 drug entries, 800 FDA-approved small molecules, and 14,000 protein or drug target sequences. DrugBank combines drug data with drug-target information this, in turn, can provide potential cues for various applications in cancer biology including in silico drug target discovery, drug design, drug interaction prediction, etc. In a study employing DrugBank, Augustyn et al. (165) evaluated potential therapeutic targets of ASCL2 genes in lung cancers, while Han et al. (166) determined synergistic combinations of drug targets in K562 chronic myeloid leukemia (CML) cells to dissect functional genetic interaction (GI) networks. Further to evaluate drugs in light of the patient's genomic signature, the PanDrugs (56) database was established in 2019. The platform currently hosts data from 24 sources and 56297 drug-target information along with 9092 unique compounds and 4804 genes. Fernández-Navarro et al. (167) prioritized personalized drug treatments using PanDrugs, for Acute T-cell lymphoblastic leukemia (T-ALL) patients. Altogether, the availability of voluminous high-resolution biomolecular data has enabled the development of a quantitative understanding of aberrant mechanisms underpinning hallmarks of cancer as well as create avenues for personalized therapeutic insights. The need to prognosticate system-level outcomes in light of oncogenic dysregulation (168, 169) has led researchers to develop integrative data-driven computational models (170) (171) (172) (173) (174) (175) (176) (177) . Such models can help decode emergent mechanisms underpinning tumorigenesis as well as aid in the development of patient-centered therapeutic strategies (170) (171) (172) (173) (174) (175) (176) (177) . These in silico models can be broadly grouped into four salient sub-scales as biomolecular (178) (179) (180) , environment (181) (182) (183) , cell level (184, 185) , and multi-scale cancer models (186-188) ( Figure 2 ). In silico biomolecular models of cancer can be classified into (i) genome-scale, (ii) transcriptomescale, (iii) proteome-scale, (iv) metabolome-scale models. (190) employed an in silico pipeline to evaluate Staphylococcal Enterotoxin B for DNA-based vaccine for cancer therapy. A similar genome-scale model of DNA damage and repair was proposed by Smith et al. (191) to evaluate proton treatment in cancer ( Figure 2A ). (ii) Transcriptome-scale Models: In silico models developed using transcriptomic expression data can assist in comparing gene expressions in cancer for investigating genetic heterogeneity in tumorigenesis and cancer development (192) as well as towards precision therapy (193) (Figure 2B ). In 2003, Huang et al. (194) developed a mathematical model using a large-scale transcriptional dataset of breast cancer patients to elucidate patterns of metagenes for nodal metastases and relapses. In another large-scale cancer transcriptomics study, 3,000 patient samples from nine different cancer types were used to decode the genomic evolution of cancer by Cheng et al. (195) . In 2013, Chen et al. (196) employed an in silico pipeline which helped identify 183 new tumor-associated gene candidates with the potential to be involved in the development of hepatocellular carcinoma (HCC), while, in 2014, Agren et al. (197) reported a personalized transcriptomic data-based model to identify anticancer drugs for HCC. In 2019, Béal et al. (198) reported a logical network modeling pipeline for personalized cancer medicine using individual breast cancer patients' data using existing gene expression databases. The pipeline was validated in 2021 (199) , using in silico personalized logical models to investigate melanomas and colorectal cancers in response to BRAF treatments. In a similar study conducted in 2019, Rodriguez et al. (200) developed a mathematical model for breast cancer using transcriptional regulation data to predict hypervariability in a large dynamic dataset and reveal the basis of expression heterogeneity in breast cancer. (iii) Proteome-scale Models: To capture the quantitative aspects of biomolecular regulations and for functional studies (88, 89) , data-driven proteomic-based cancer models are essential ( Figure 2C ). Such models can be particularly helpful in diagnostic as well as prognostic purposes as well as for monitoring response to treatment (88, 89) . In a study employing proteome-level information, in 2011, Baloria et al. (201) carried out an in silico proteome-based characterization of the human epidermal growth factor receptor 2 (HER-2) to evaluate its immunogenicity in an in silico DNA vaccine. Akhoon et al. (202) simplified this approach with the development of a new prophylactic in silico DNA vaccine using IL-12 as an adjuvant. In 2017, Fang et al. (203) further employed proteome level data towards predicting in silico drug-target interactions for targeted cancer therapeutics, while in 2018, Azevedo et al. (204) designed novel glycobiomarkers in bladder cancer. Recently, in 2020, Lee et al. (205) have reported an integrated proteome model of macrophage migration in a complex tumor microenvironment. However, proteome-level models are limited in their ability to provide a complete analysis of the biomolecules present in a cell since they lack information on low molecular weight biomolecular compounds such as metabolites (112) . (211) used an integrative in silico pipeline to evaluate the anti-cancerous effects of Syzygium aromaticum employing data from the Human Metabolome Database (114) . Integrative mathematical models of environmental cues and extracellular matrix can help researchers abstract tumor microenvironments. Such data-driven models can be used to study angiogenesis (212) , cell adhesion (213) , and vasculature (214) ( Figure 2E ). Amongst initial attempts at developing cancer environment-based in silico models, in 1972, Greenpan et al. (181) developed a solid carcinoma in silico model to evaluate cancer cell behavior in limited diffusion settings. In 1976, the model was expanded (182) to investigate tumor growth in asymmetric conditions. In 1996, Chaplain developed a mathematical model to elucidate avascular growth, angiogenesis, and vascular growth in solid tumors (183) . Anderson and Chaplain (215) , in 1998, expanded this strategy and reported a continuous and discrete model for tumor-induced angiogenesis. This modeling approach was further augmented in 2005 by Anderson (216) to a hybrid mathematical model of a solid tumor to study cellular adhesion in tumor cell invasion. Organ-specific metastases and associated survival ratios in small cell lung cancer patients have been modeled and evaluated (217) using similar models. To model cell population-level behavior in cancer, researchers are increasingly developing innovative cell line in silico models which can complement in vivo wet-lab experiments, while overcoming wet-lab limitations (218) ( Figure 2F ). Such models are employed to investigate cellto-cell interactions and evaluate physical features of the synthetic extracellular matrix (ECM) (218) , etc (184, 219) . Amongst initial attempts at developing in silico cell line models, in 1989, Shackney et al. (184) reported an in silico cancer cell model to study tumor evolution. Results showed an association between discrete aneuploidy peaks with the activation of growthpromoting genes. In 2007, Aubert et al. (219) developed an in silico glioma cell migration model and validated cell migration preferences for homotype and heterotypic gap junctions with experimental results. Gerlee and Nelander (185) expanded this work, in 2012, to investigate the effect of phenotype switching on glioblastoma growth. Although cell-based cancer models helped provide scale-specific insights into cancer, however, they remain limited in investigating the spatiotemporal tissue diversity and heterogeneity in cancer patients. Recently, data-driven multi-scale models are becoming increasingly popular in cancer (220) ( Figure 2G ). One of the earliest attempts at developing multi-scale cancer models was in 1985 when Balding developed a mathematical model to demonstrate tumor-induced capillary growth (212) . Summarily, data-integrative computational models have now assumed the forefront in decoding the complex biomolecular regulations involved in cancer and are increasingly been employed for the development of personalized preclinical models as well as therapeutics design (231). Timeline of salient in silico scale-specific and multi-scale cancer models, along with PubMed yearly report (1990-2020) to display the evolutionary trends seen in the development of (A) genome-scale cancer models, (B) Transcript-level cancer models, (C) Proteome-scale models, (D) Metabolome scale models, (E) Environment-based models, (F) Cell-level models, and (G) Multiscale cancer models. Over the past decade, in silico modeling of cancer has gained significant popularity in systems biology research (170) (171) (172) (173) (174) (175) (176) (177) . In particular, data-drive computational models are now acting as an enabling technology for precision medicine and personalized treatment of cancer. To date, several single and multi-scale software platforms have been reported to model biomolecular (180, (232) (233) (234) (235) (236) (237) (238) (239) , environmental (240), cell-level (241) (242) (243) , and multi-scale (244-246) information into coherent in silico cancer models ( Figure 3 ). Software platforms aimed at modeling biomolecular entities, abstract information from published literature as well as high-throughput technologies, and model them using a Boolean modeling approach or a differential equations modeling strategy. GIMsim also implemented multi-valued logical functions, useful in simulating qualitative dynamical behavior in cancer research. However, the platform was unable to program automatic theoretical predictions, moreover, it only employed qualitative analysis approaches and could not be used to accurately map cell fates based on quantitative biomolecular expression data. Taken together, classical qualitative Boolean modeling approaches remain limited in developing predictive cancer models that could leverage quantitative biomolecular expression data generated from next-generation proteomics and related-sequencing projects. (267), and colorectal cancer (268) . Although Boolean models have proven to be a powerful tool in modeling complex biomolecular signaling networks, however, these models are unable to describe continuous concentration, and cannot be used to quantify the timedependent behavior of biological systems, necessitating the need to switch to quantitative differential equations (269) . As a result, numerous stand-alone and web-based tools have been developed to build continuous network models to help describe the temporal evolution of biomolecules towards elucidating more accurate cell fate outcomes from quantitative expression data (Supplementary Table 8 ). Amongst initial attempts at developing such software, GEPASI (GEneral PAthway Simulator) was reported by Pedro Mendes et al. (239) , in 1993. GEPASI is a stand-alone simulator that facilitates formulating mathematical models of biochemical reaction networks. GEPASI can also be used to perform parametric sensitivity analysis using an automatic pipeline that evaluates networks in light of exhaustive combinatorial input parameters. To facilitate the development of environmental models that can help investigate inter-, intra-, and extracellular interactions between cellular network models and their dynamic environment, several software and platforms have been reported (240, 279) . These platforms employ discrete, continuous, and hybrid approaches to develop models of cellular microenvironments towards setting up specific biological contexts such as normoxia, hypoxia, Warburg effect, etc (Supplementary Table 9 ). In 2014, Starruß et al. (240) published Morpheus, a platform for modeling complex tumor microenvironment. Morpheus leverages a cellular potts modeling approach to integrate and stimulate cell-based biomolecular systems for modeling intra-and extra cellular dynamics. In a case study using Morpheus, Felix et al. (280) evaluated pancreatic ductal adenocarcinoma's adaptive and innate immune response levels, while Meyer et al. (281) investigated the dynamics of biliary fluid in the liver lobule. Although Morpheus is a widely employed modeling software, however, its diffusion solver is limited in its capacity to model large 3D domains. Towards modeling fast simulations for larger cellular systems, the Finite Volume Method for biological problems (BioFVM) software (279) was reported by Ghaffarizadeh et al., in 2016 . BioFVM is an efficient transport solver for single as well as multi-cell biological problems such as excretion, decomposition, diffusion, and consumption of substrates, etc (282) . In a case study using BioFVM, Ozik et al. (283) evaluated tumor-immune interactions, while Wang et al. (284) elucidated the impact of tumor-parenchyma on the progression of liver metastasis. BioFVM, however, relies on its users to have programming-based knowledge to develop their models, which limits its translational potential. Towards minimizing programming requirement, SALSA (ScAffoLd SimulAtor) was reported by Cortesi et al. (218) in 2020. SALSA is general-purpose software that employs a minimum programming requirement, a significant advantage over its predecessors. The platform, in particular, has been useful in studying cellular diffusion in 3D cultures. This recent tool was validated in 2021, with a case study that evaluated and predicted therapeutic agents in 3D cell cultures (285) . Towards modeling cancer cell-specific behaviors such as cellular adhesion, membrane transport, loss of cell polarity, etc several software have been reported which can help develop in silico cancer cellular models (Supplementary Table 10 (291) with computer-aided design (CAD) functionality which enabled faster simulation and associated analysis. The platform employed a modular approach for constructing networks and provides built-in features for ease in network construction, robustness analysis, and evaluating networks using existing databases. The evolutionary trend for TinkerCell's platform adaptability and flexibility is highlighted in Figure 4 , which shows a gradual shift from being a model specific platform to a domain modelling one. In a study employing TinkerCell, Renicke et al. (292) constructed a generic photosensitive degron (psd) model to investigate protein degradation and cellular function, while Chandran et al. (293) reported computer-aided biological circuits. Multi-scale cancer modeling approaches bring together scale-specific models towards undertaking an integrative analysis of heterogeneous experimental data by building coherent and biologically plausible models (294) (295) (296) (297) . Several multi-scale modeling platforms have been reported to help develop multiscale cancer models (244) (245) (246) (Supplementary Table 11 ). Amongst these, the REcursive Porous Agent Simulation Toolkit (Repast) (298, 299) published in 2003, provides a free and open-source tool for modeling and simulating agent-based models, with high-performance computing (HPC) capability. Repast toolkit was employed in 2007, by Folcik et al. (300) to develop an agent-based model which was then used to study interactions between cells and the immune system. Similarly, Mehdizadeh et al. (301) used Repast to model angiogenesis in porous biomaterial scaffolds. Although Repast can be used for simulating several types of evolutionary trends between agents, there is no established guideline for selecting a mechanism to model such trends, hindering its use by naïve users. Moreover, Repast does not have a GUI or a software development kit (SDK) interface for implementing subcellular mechanisms e.g., gene, protein, and metabolic networks. In contrast, CompuCell (295) (303) for evaluating potential new approaches for therapeutic intervention for angiogenesis. Although CompuCell provides an intuitive framework modeling paradigm, however, the platform core is not conducive to multi-scale cancer modeling. The focus of the software is primarily multi-agent simulations rather than multi-scale cancer modeling. This poses a significant challenge in the utilization of the software. In 2013, CHASTE (296) (Cancer Heart and Soft Tissue Environment) was launched, which provides a computational simulation pipeline for mathematical modeling of complex multi-scale models. Users can employ CHASTE for a wide range of problems involving on and off-lattice modeling workflows. CHASTE has also previously been employed to model colorectal cancer crypts. Nonetheless, CHASTE does not have a GUI and can only be executed by command line text commands. Furthermore, it requires recompilation on part of the modeler to use the code updates performed by the group. To further improve the multi-scale modeling approach for investigating cancer, in 2013, Chaudhary et al. (297) published ELECANS (Electronic Cancer System). ELECANS had an intuitive but rigid GUI along with a programmable SDK besides the lack of a high-performance simulation engine. ELECANS was employed to model the mitochondrial processes in cancer towards elucidating the hidden mechanisms involved in the Warburg effect (304) . Although ELECANS provided a feature-rich environment for constructing multi-scale models, however, the platform lacked a biomolecular network integration pipeline, and it also placed a heavy programming requirement on its users. In contrast, in 2018, PhysiCell (305) was reported for 2D and 3D multi-cell off-lattice agent-based simulations. PhysiCell is coupled with BioFVM (279)'s finite volume method to model multi-scale cancer systems (283) . In a salient example, Wang et al. (284) employed PhysiCell to model liver metastatic progression. In 2019, PhysiCell's agent-based modeling features and MaBoss's Boolean cell signaling network feature were coupled together to develop an integrated platform, PhysiBoss (306) . As a result, PhysiBoss provided an agent-based modeling environment to study physical dimension and cell signaling networks in a cancer model. In 2020, Colin et al. (307) employed PhysiBoss's source code to model diffusion in oocytes during prophase 1 and meiosis 1, while Getz et al. (308) proposed a framework using PhysiBoss to develop a multi-scale model of SARS-CoV-2 dynamics in lung tissue. Recently, in 2021, Gondal et al. (309) reported Theatre for in silico Systems Oncology (TISON), a web-based multi-scale "zero-code" modeling and simulation platform for in silico oncology. TISON aims to develop single or multi-scale models for developing personalized cancer therapeutics. To exemplify the use case for TISON, Gondal et al. employed TISON to model colorectal tumorigenesis in Drosophila melanogaster's midgut towards evaluating efficacious combinatorial therapies for individual colorectal cancer patients (236) . Summarily, multi-scale modeling software have enabled the development of biologically plausible cancer models to varying degrees. These platforms, however, fall short of providing a generic and high-throughput environment that could be conveniently translated in clinical settings. Highlighting the need for a generic, data-driven, zero-code software requirement. In silico multi-scale cancer models, annotated with patient-specific biomolecular and clinical data, can help decode complex mechanisms underpinning tumorigenesis and assist in clinical decisionmaking (310, 311) . Clinically-driven in silico multi-scale cancer models simulate in vivo tumor growth and response to therapies across biocomplexity scales, within a clinical environment, towards evaluating efficacious treatment combinations. To facilitate the development of multiscale cancer models, several large-scale program projects have been launched (Supplementary Table 12 Figure 5 ). Here, we review and evaluate five salient projects for multi-scale cancer modeling towards their clinical deployment. The ACGT project (312) , launched in 2007, proposed to develop Clinico-Genomic infrastructure for organizing clinical and genomic data towards investigating personalized therapeutics regimens for an individual cancer patient (317) . The ACGT platform provides an open-source and open-access infrastructure designed to support the development of "oncosimulators" to help clinicians accurately compare results from different clinical trials and enhance their efficiency towards optimizing cancer treatment (318, 319) . The ACGT framework employs molecular and clinical data generated from different sources including whole genome sequencing, histopathological, imaging, molecular, and clinical data, etc. to develop simulators for mimicking clinical trials. Personalized panomics data employed to develop oncosimulators in ACGT is extracted from real patients which enables the oncosimulators to be clinically relevant for predictive purposes. Additionally, ACGT provides data retrieval, storage, integrative, anonymization, and analysis as well as results presentation capabilities. Using the platform, in 2008, Kolokotroni et al. (320) developed a personalized, spatiotemporal oncosimulator model of breast cancer to mimic a clinical trial based on protocols outlined in the Trail of Principle (TOP), towards evaluating the model response to chemotherapeutic treatment in neoadjuvant settings (321) . Similarly, in 2009, Graf et al. (322, 323) modeled nephroblastoma oncosimulator, a childhood cancer of the kidney, based on a clinical trial run by the International Society of Paediatric Oncology (SIOP) for simulating tumor response to therapeutic regimens in the clinical trials. The results generated from the TOP and SIOP trials enabled the ACGT oncosimulators to adapt in light of real clinical conditions and the software to be validated against multi-scale patient data. The focus of ACGT oncosimulators, however, is limited to existing clinical trials for predicting efficacious treatment combinations. Towards establishing a platform for the development of composite multi-scale models for simulating malignant tumor models, in 2008, ContraCancrum project (313) was initiated. ContraCancrum aimed to develop a multi-scale computational framework for translating personalized cancer models into clinical settings towards simulating malignant tumor development and response to therapeutic regimens. For that, the Individualized MediciNe Simulation Environment (IMENSE) platform (324, 325) was established, to undertake the oncosimulator development process. The platform was employed for molecular and clinical data storage, retrieval, integration, and analysis. Oncosimulators, developed under the ContraCancrum project, employ patient data across biologically and clinically relevant scales including molecular, environmental, cells, and tissues level. These oncosimulators can be used to optimize personalized cancer therapeutics for assisting clinician decision-making process. To date, several oncosimulators have been developed, under the ContraCancrum project (31, 313, 323, [325] [326] [327] [328] [329] [330] [331] [332] . In particular, the initial validation of the ContraCancrum workflow was performed using two case studies; glioblastoma multiforme (GBM) (313, 326, 332) and non-small cell lung cancer (NSCLC) (313, 330, 331) . In 2010, Folarin and Stamatakos (333) developed a glioblastoma oncosimulator using personalized molecular patient data to evaluate treatment response under the effect of a chemotherapeutic drug (temozolomide) (324) . Similarly, Roniotis et al. (332) developed a multi-scale finite elements workflow to model glioblastoma growth, while Giatili et al. (326) outlined explicit boundary condition treatment in glioblastoma using an in silico tumor growth model. The results from the case studies were validated by comparing in silico prediction with pre-and post-operative imaging and clinical data (313, 328) . Moreover, The ContraCancrum project hosts more than 100 lung patients' tumor and blood samples (313) . This data is employed to develop clinically validated in silico multilevel cancer models for NSCLC using patient-specific data (330) . In 2010, using a biochemical oncosimulator, Wan et al. (330) investigated the binding affinities for AEE788 and Gefitinib tyrosine kinase inhibitor against mutated epidermal growth factor receptor (EGFR) for NSCLC treatment. Similarly, Wang et al. (331) developed a 2D agent-based NSCLC model to investigate proliferation markers and evaluated ERK as a suitable target for targeted therapy. Although ContraCancrum's project has created numerous avenues for multilevel cancer model development, however, the platform is limited to only specific types of cancer for which data is internally available on the platform. Towards improving clinical deployment capabilities of oncosimulators, another pilot project: the personalized medicine (p-medicine) project was launched in 2011 (314) . The main aim of pmedicine was to create biomedical tools facilitating translation of current medicine to P5 medicine (predictive, personalized, preventive, participatory, and psycho-cognitive) (334) . For that, the p-medicine portal provides a web-based environment that hosts specifically-purpose tools for personalized panomics data integration, management, and model development. The portal has an intuitive graphical user interface (GUI) with an integrated workbench application for integrating information from clinical practices, histopathological imaging, treatment and omics data, etc. Computational models developed under p-medicine workflow, are quantitatively adapted to clinical settings since they are derived using real multi-scale data. Several multi-scale cancer simulation models (oncosimulators) (314, 334) oncosimulator for evaluating the efficacy of prednisolone (a steroid medication). This study was further augmented, in 2015, by Kolokotroni et al. (340) to investigate the potential cytotoxic side effects of prednisolone. Later in 2017, Ouzounoglou et al. (341) expanded their ALL oncosimulator model to a hybrid oncosimulator for predicting pre-phase treatments for ALL patients. The validation of these models was undertaken using clinical trial data in pre and posttreatment (342) . Although, p-medicine presents a state-of-the-art in silico multi-scale cancer modeling environment, however, the project is limited in its application for determining individual biomarkers for potential novel therapy identification. Moreover, the project is limited to its niche set of tools and models that cannot be integrated with other similar model repositories and platforms. In 2012, a transatlantic USA-EU partnership was initiated with the launch of Transatlantic Tumor Model Repositories (TUMOR) (315) . TUMOR provides an integrated, interoperable transatlantic research environment for developing a clinically-driven cancer model repository. The repository aimed to integrate computational cancer models developed by different research groups. TUMOR's transatlantic aim was to couple models from ACGT and ContraCancrum projects with those at the Center for the Development of a Virtual Tumor (CViT) (343) as well as other relevant centers. TUMOR is predicted to serve as an international clinical translation, interoperable and validation platform for in silico oncology hosting multi-scale cancer models from different cancer model repositories and platforms such as E-Cell (344), CellML (345) , FieldML (346) , and BioModels (39,347). To support model data interoperability between platforms, TumorML (Tumor model repositories Markup Language) (347) was developed towards facilitating interdata operability in the TUMOR project. The TUMOR environment also offers a wide range of additional services supporting predictive oncology and individualized optimization of cancer treatment. For example, the platform allows remote access of predictive cancer models in hospitals and to clinicians for the development of quantitative cancer research and personalized cancer therapy model. TUMOR environment also incorporates deterministic as well as stochastic models through COPASI simulator (246) . An automatic validation pipeline is also embedded for the execution and deployment of these models in clinical settings (315 (349) . Similarly, in 2014 Sakkalis et al. (350) employed the TUMOR platform to interlink and couple three independent glioblastoma-specific cancer models (EGFR signaling (351) , cancer metabolism (352) , Oncosimulator (350, 353) ), reported by different research groups. The resultant model was used to investigate the impact of radiation and temozolomide (chemotherapy) on glioblastoma multiforme to evaluate treatment effectiveness. Another transatlantic project Computational Horizons In Cancer (CHIC) project (316) launched in 2013, aimed to provide an oncosimulator modeling platform for in silico oncology. CHIC was initiated to develop and implement predictive oncology and individualized multi-scale cancer modeling tools towards assisting quantitative cancer research and personalized cancer therapy. The workflow and tools established under the ambient of the CHIC project allowed the development of robust, interoperable, and collaborative in silico models in cancer and normal conditions (316) . The CHIC project also proposed a pipeline to translate the model towards supporting clinicians to make optimal personalized treatment plans for individual patients. To this end, several models are created using CHIC such as non-small cell lung cancer (354) , glioblastoma (355) , leukemia model (356), etc. These models furnish a quantitative understanding of tumorigenesis towards providing avenues for promoting individual cancer patient treatment combinations. One such model reported by Kolokotroni et al. (354) evaluated the efficacy of cisplatin-based therapy for NSCLC patients using in silico multi-scale cancer model. While, in 2015, Antonopoulos and Stamatakos (355) modeled the infiltration of glioblastoma cells in normal brain regions using a novel treatment. In 2017, Stamatakos and Giatili (357) extended glioblastoma oncosimulator for modeling tumor growth using reaction-diffusion numerical handling based on multi-scale panomics data. They further proposed a clinical pipeline to translate the model into clinical settings towards supporting clinicians to make optimal personalized treatment plans for individual patients. Ouzounoglou et al. (356) developed an in silico multi-scale leukemia oncosimulator model towards modeling deregulations in the G1/S pathway to investigate the altered function of retinoblastoma in ALL patients. However, a clinical translation of these models is currently in the works (358). Timeline highlighting salient project platforms for developing realistic and clinically-driven multiscale cancer models, along with their associated leading case studies. In this work, we have evaluated the use of data-driven multi-scale cancer models in deciphering complex biomolecular underpinnings in cancer research towards developing personalized therapeutics interventions for clinical decision-making. Specifically, we have discussed the chronological evolution of online cancer data repositories that host high-resolution datasets from multiple spatiotemporal scales. Next, we evaluate how this data drives single-and multi-scale systems biology models towards decoding complex cancer regulation in patients. We then track the development of various modeling software and their applications in enhancing the translational role of cancer systems biology models in clinics. We conclude that the contemporary multi-scale modeling software line-up remains limited in their clinical employment due to the lack of a generic, zero-code, panomic-based framework for translating research models into clinical settings. Such a framework would help annotate in silico cancer models developed using single and multi-scale databases (69, (359) (360) (361) (362) (363) (364) (365) . The framework should also provide an environment for developing the extra-cellular matrix of a cancer cell which can then be integrated into cellular models. Existing environment (42,43) and cell line databases (45-47) need to be integrated to design environmental models along with biologically plausible cell line structures. These cell lines could then be assembled into three-dimensional geometries to create multi-scale in silico organoids. The pipeline should also furnish capabilities such as a convenient import workflow for clinical data integration through histopathological image data repositories (48-50) for designing biologically accurate organoid structures based on each cancer patient's underlying cellular morphology. Once the personalized multi-scale model has been constructed, the pipeline would allow investigation into the temporal evolution of the multi-scale organoid under personalized inputs and user-designed biomolecular entities. Data generated from the multi-scale model simulation can be analyzed to elicit biomolecular cues for each cancer patient as well as determine its role. Taken together, a translational in silico systems oncology pipeline is the need of the hour and will help develop and deliver personalized treatments of cancer as well as substantively inform clinical decision-making processes. The authors declare that they have no conflict of interest. The supplementary tables for the manuscript titled "Navigating Multi-scale Cancer Systems Biology towards Model-driven Personalized Therapeutics" is available online. National Cancer Act of 1971 -National Cancer Institute The war on cancer: have we won the battle but lost the war? War on Cancer" and its impact National Cancer Act of 1971 Pharmacogenomics and patient care: one size does not fit all The growing role of precision and personalized medicine for cancer treatment Regulation of spatiotemporal patterning in artificial cells by a defined protein expression system Hybrid models of tumor growth Oncogenic Signaling Pathways in The Cancer Genome Atlas Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Identifying multi-hit carcinogenic gene combinations: Scaling up a weighted set cover algorithm using compressed binary matrix representation on a GPU Intra-tumour diversification in colorectal cancer at the single-cell level Cancer classification in the genomic era: five contemporary problems The hallmarks of cancer Hallmarks of cancer: the next generation Recent advances in the reconstruction of metabolic models and integration of omics data Pattern of self-organization in tumour systems: Complex growth dynamics in a novel brain tumour spheroid model Tissue-scale, personalized modeling and simulation of prostate cancer growth DrugBank: A knowledgebase for drugs, drug actions and drug targets PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data Systems biology and multi-omics integration: Viewpoints from the metabolomics research community The GenBank genetic sequence databank Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients The Ensembl genome database project Genome-wide association study identifies novel breast cancer susceptibility loci Regulation of transcription and gene expression in eukaryotes Next Generation : Sequencing & Applications Transcriptome Analysis on RNA-seq Data Integration of Transcriptome, Proteome, and Metabolome Provides Insights into How Calcium Enhances the Mechanical Strength of Herbaceous Peony Inflorescence Stems The Gene Expression Omnibus Database MICU1 drives glycolysis and chemoresistance in ovarian cancer The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website Hyperactive Ras in developmental disorders and cancer Characterizing the cancer genome in lung adenocarcinoma The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge Comprehensive identification of mutational cancer driver genes across 12 tumor types Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell International Cancer Genome Consortium Data Portal-a one-stop shop for cancer genomics data Dissecting the genomic complexity underlying medulloblastoma APOBEC3B is an enzymatic source of mutation in breast cancer Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Integrative Clinical Genomics of Advanced Prostate Cancer Mutations associated with acquired resistance to PD-1 blockade in melanoma Genomic analyses identify molecular subtypes of pancreatic cancer The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis Discordant protein and mRNA expression in lung adenocarcinomas Is proteomics the new genomics? Proteomics: Technologies and Their Applications Identification and analysis of the RNA degrading complexes and machinery of Giardia lamblia using an in silico approach Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity Comparative analyses of the variation 38 of the transcriptome and proteome of Rhodobacter sphaeroides throughout growth Proteomics: An atlas of expression A human protein atlas based on antibody proteomics A human protein atlas for normal and cancer tissues based on antibody proteomics MALDI Profiling of Human Lung Cancer Subtypes A genomewide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cells New Goals for the U.S. Human Genome Project: 1998-2003. Science (80-) The human proteome project: current state and future direction HUPO ' s Human Proteome Project : the next big thing ? Qualitative and Quantitative Expression Status of the Human Chromosome 20 Genes in Cancer Tissues and the Representative Cell Lines Reproducible Quantification of Cancer-Associated Proteins in Body Fluids Using Targeted Proteomics Proteogenomic characterization of human colon and rectal cancer Proteomic profiling of human plasma for cancer biomarker discovery Proteogenomics connects somatic mutations to signalling in breast cancer Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer A Highly Complex Organization of the Regulatory Region of the Human CYP19 (Aromatase) Gene Revealed by the Human Genome Project The biology/disease-driven human proteome project (B/D-HPP): Enabling protein research for the life sciences community The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome Chromosomecentric human proteome project: Deciphering proteins associated with glioma and neurodegenerative disorders on chromosome 12 Qualitative and Quantitative Expression Status of the Human Chromosome 20 Genes in Cancer Tissues and the Representative Cell Lines Proteomics integrated with metabolomics: analysis of the internal causes of nutrient changes in alfalfa at different growth stages DB: the Golm Metabolome Database HMDB 4.0: the human metabolome database for 2018 Metabolomics Workbench: An international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools Is serum or plasma more appropriate for intersubject comparisons in metabolomic studies? An assessment in patients with small-cell lung cancer Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancerspecific profiles Reconstruction of Genome-Scale Active Metabolic Networks for 69 Human Cell Types and 16 Cancer Types Using INIT Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia Dietary Biomarker Discovery using Metabolomics and Application to Understanding Breast Cancer Etiology Kyoto Encyclopedia of Genes and Genomes Large-scale gene function analysis with the PANTHER classification system KEGG: new perspectives on genomes, pathways, diseases and drugs RNA sequencing reveals the expression profiles of circRNA and indicates that circDDX17 acts as a tumor suppressor in colorectal cancer Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis The Human Gene Mutation Database (HGMD) and its exploitation in the fields of personalized genomics and molecular evolution IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype The MetaCyc Database Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles BIND--The Biomolecular Interaction Network Database Differential Expression of Novel Tyrosine Kinase Substrates during Breast Cancer Development * SZGR: a comprehensive schizophrenia gene resource Controllability analysis of the directed human protein interaction network identifies disease genes and drug targets DIP: the database of interacting proteins Network-based pipeline for analyzing MS data: An application toward liver cancer Identification of microRNA-regulated autophagic pathways in plant lectin-induced cancer cell death Bioinformatic identification of potential autocrine signaling loops in cancers from gene expression profiles STRING: known and predicted protein-protein associations, integrated and transferred across organisms The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer Natural immunity to cancer in humans Signaling pathways have an inherent need for noise to acquire information DNA-based artificial molecular signaling system that mimics basic elements of reception and response Intrinsic limits of information transmission in biochemical signalling motifs Microenvironmental regulation of tumor progression and metastasis The human protein atlas: A spatial map of the human proteome Pieces of use puzzle: Expressed sequence tags and the catalog of human genes Extracting a lowdimensional description of multiple gene expression datasets reveals a potential driver for tumor-associated stroma in ovarian cancer Heat Shock Factor 1-dependent extracellular matrix remodeling mediates the transition from chronic intestinal inflammation to colon cancer Cancer Cell Lines Are Useful Model Systems for Medical Research. Cancers (Basel) The landscape of cancer cell line metabolism Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell National Cancer Institute MGH Institute of Health Professionals The public cancer radiology imaging collections of The Cancer Imaging Archive. Sci data MR imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of MammaPrint, oncotype DX, and PAM50 gene assays A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images The design, analysis and application of mouse clinical trials in oncology drug development Comparing exponential and exponentiated models of drug demand in cocaine users DrugBank: a comprehensive resource for in silico drug discovery and exploration ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data Systems oncology: Towards patient-specific treatment regimes informed by multiscale mathematical modelling Systems oncology: toward the clinical application of cancer systems biology Microenvironment driven invasion: A multiscale multimodel investigation Multi-scale models of cell and tissue dynamics A multiscale model of the bone marrow and hematopoiesis Multiscale Modeling of Tumorigenesis Induced by Mitochondrial Incapacitation in Cell Death Multi-scale modeling of the CD8 immune response Blood vessel tortuosity selects against evolution of aggressive tumor cells in confined tissue environments: A modeling approach Multicompartment cell-based modeling of confined migration: regulation by cell intrinsic and extrinsic factors Mathematical Modeling, Analysis, and Simulation of Tumor The gene for familial polyposis coli maps to the long arm of chromosome 5 A mathematical computer simulation model for the development of colonic polyps and colon cancer Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model Models for the Growth of a Solid Tumor by Diffusion On the growth and stability of cell cultures and solid tumors Avascular growth, angiogenesis and vascular growth in solid tumours: The mathematical modelling of the stages of tumour development Model for the Genetic Evolution of Human Solid Tumors The Impact of Phenotypic Switching on Glioblastoma Growth and Invasion In-silico models of stem cell and developmental systems Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model Identification of Critical Molecular Components in a Multiscale Cancer Model Based on the Integration of Monte Carlo, Resampling, and ANOVA Robust Detection of DNA Hypermethylation of ZNF154 as a Pan-Cancer Locus with in Silico Modeling for Blood-Based Diagnostic Development Silico Analyses of Staphylococcal Enterotoxin B as a DNA Vaccine for Cancer Therapy Silico Models of DNA Damage and Repair in Proton Treatment Planning: A Proof of Concept Transcriptome: connecting the genome to gene function Conceptual model of integrated approach for in silico knowledge data discovery for breast cancer diagnostics and precision therapy Gene expression predictors of breast cancer outcomes A Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer Types In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling Personalization of Logical Models With Multi-Omics Data Allows Clinical Stratification of Patients Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancers Intrinsic Dynamics of a Human Gene Reveal the Basis of Expression Heterogeneity In silico proteomic characterization of human epidermal growth factor receptor 2 (HER-2) for the mapping of high affinity antigenic determinants against breast cancer In silico identification of novel protective VSG antigens expressed by Trypanosoma brucei and an effort for designing a highly immunogenic DNA vaccine using IL-12 as adjuvant. Microb Pathog Quantitative and Systems Pharmacology. 1. In Silico Prediction of Drug-Target Interactions of Natural Products Enables New Targeted Cancer Therapy In silico approaches for unveiling novel glycobiomarkers in cancer Integrated in silico and 3D in vitro model of macrophage migration in response to physical and chemical factors in the tumor microenvironment The Edinburgh human metabolic network reconstruction and its functional analysis Predicting selective drug targets in cancer through metabolic networks Prediction of intracellular metabolic states from extracellular metabolomic data Biomarkers are used to predict quantitative metabolite concentration profiles in human red blood cells Deep Learning Accurately Predicts Estrogen Receptor Status in Breast Cancer Metabolomics Data An integrative in silico mathematical modelling study of the anti-cancer effect of clove extract (Syzygium aromaticum) combined with in vitro metabolomics study using1hnmr spectroscopy A mathematical model of tumour-induced capillary growth A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies Continuous and discrete mathematical models of tumorinduced angiogenesis A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion Specific organ metastases and survival in small cell lung cancer An in-silico study of cancer cell survival and spatial distribution within a 3D microenvironment A model for glioma cell migration on collagen and astrocytes Modeling heterogeneous tumor growth dynamics and cell-cell interactions at single-cell and cell-population resolution A quantitative model for differential motility of gliomas in grey and white matter Development of a three-dimensional multiscale agentbased tumor model: Simulating gene-protein interaction profiles, cell phenotypes and multicellular patterns in brain cancer Multiscale Modelling of Vascular Tumour Growth in 3D: The Roles of Domain Size and Boundary Conditions Modelling of Cancer Growth, Evolution and Invasion: Bridging Scales and Models A Validated Multiscale In-Silico Model for Mechano-sensitive Tumour Angiogenesis and Growth An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia Multiscale agent-based and hybrid modeling of the tumor immune microenvironment Morphophenotypic classification of tumor organoids as an indicator of drug exposure and penetration potential The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression Comparison of Drug Inhibitory Effects (IC50) in Monolayer and Spheroid Cultures Multiscale Cancer Modeling and In Silico Oncology: Emerging Computational Frontiers in Basic and Translational Cancer Research A Boolean-based systems biology approach to predict novel genes associated with cancer: Application to colorectal cancer Boolean Network Model for Cancer Pathways: Predicting Carcinogenesis and Targeted Therapy Outcomes Robustness and Backbone Motif of a Cancer Network Regulated by miR-17-92 Cluster during the G1/S Transition Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines In silico Drosophila Patient Model Reveals Optimal Combinatorial Therapies for Colorectal Cancer Structural and functional analysis of cellular networks with CellNetAnalyzer NET-SYNTHESIS: a software for synthesis, inference and simplification of signal transduction networks Dynamics , Steady States and Control of Biochemical and Other Systems Morpheus: a user-friendly modeling environment for multiscale and multicellular systems biology E-CELL: Software environment for whole-cell simulation Computational cell biology: The Virtual Cell software environment Virtual Cell modelling and simulation software environment Ye Li and LML. The Virtual Cell Modeling and Simulation Software Environment A computational systems biology software platform for multiscale modeling and simulation: Integrating whole-body physiology, disease biology, and molecular reaction networks COPASI -A COmplex PAthway SImulator Metabolic stability and epigenesis in randomly constructed genetic nets The logical analysis of continuous, non-linear biochemical control networks The NetBuilder' project: development of a tool for constructing, simulating, evolving, and analysing complex regulatory networks Boolean network simulations for life scientists Simboolnet-A cytoscape plugin for dynamic simulation of signaling networks FluxAnalyzer: exploring structure, pathways, and flux distributions in metabolic networks on interactive flux maps Dynamics of DNA Damage Induced Pathways to Cancer A MAPK-Driven Feedback Loop Suppresses Rac Activity to Promote RhoA-Driven Cancer Cell Invasion Dynamical and Structural Analysis of a T Cell Survival Network Identifies Novel Candidate Therapeutic Targets for Large Granular Lymphocyte Leukemia Network modeling of TGFβ signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and Wnt pathway activation Logical modelling of regulatory networks with GINsim 2.3. Biosystems [Internet Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling A modeling approach to explain mutually exclusive and co-occurring genetic alterations in bladder tumorigenesis MaBoSS 2.0: an environment for stochastic Boolean modeling Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of BoolNet-an R package for generation, reconstruction and analysis of Boolean networks Inference of Network Dynamics and Metabolic Interactions in the Gut Microbiome Mathematical Modelling of Molecular Pathways Enabling Tumour Cell Invasion and Migration ATLANTIS -Attractor Landscape Analysis Toolbox for Cell Fate Discovery and Reprogramming. Sci Rep Quantifying robustness and dissipation cost of yeast cell cycle network: the funneled energy landscape perspectives Attractor Landscape Analysis Reveals Feedback Loops in the p53 Network That Control the Cellular Response to DNA Damage Attractor landscape analysis of colorectal tumorigenesis and its reversion Transforming Boolean models to continuous models: methodology and application to Tcell receptor signaling 7-Nitro-2,1,3-benzoxadiazole Derivatives, a New Class of Suicide Inhibitors for Glutathione S-Transferases: MECHANISM OF ACTION OF POTENTIAL ANTICANCER DRUGS* Modeling cancer glycolysis COPASI -A COmplex PAthway SImulator Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway Dynamic Modelling of Pathways to Cellular Senescence Reveals Strategies for Targeted Interventions CellDesigner: a process diagram editor for gene-regulatory and biochemical networks Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration A comprehensive modular map of molecular interactions in RB/E2F pathway Integrative Modelling of the Influence of MAPK Network on Cancer Cell Fate Decision BioFVM: An efficient, parallelized diffusive transport solver for 3-D biological simulations MicroRNA modulated networks of adaptive and innate immune response in pancreatic ductal adenocarcinoma A Predictive 3D Multi-Scale Model of Biliary Fluid Dynamics in the Liver Lobule Learning-accelerated discovery of immunetumour interactions High-throughput cancer hypothesis testing with an integrated PhysiCell-EMEWS workflow Impact of tumor-parenchyma biomechanics on liver metastatic progression: a multi-model approach Development and validation of an in-silico tool for the study of therapeutic agents in 3D cell cultures In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway The Virtual Cell: a software environment for computational cell biology Cell Shape and Negative Links in Regulatory Motifs Together Control Spatial Information Flow in Signaling Networks Persistent cAMP-Signals Triggered by Internalized G-Protein-Coupled Receptors TinkerCell: modular CAD tool for synthetic biology A LOV2 Domain-Based Optogenetic Tool to Control Protein Degradation and Cellular Function Computer-aided design of biological circuits using TinkerCell RePast : An Extensible Framework for Agent Simulation CompuCell, a multi-model framework for simulation of morphogenesis Chaste: An Open Source C++ Library for Computational Physiology and Biology ELECANS--an integrated model development environment for multiscale cancer systems biology Proceedings of the first annual North American Association for Computational Social and Organizational Science conference Complex adaptive systems modeling with Repast Simphony The Basic Immune Simulator: An agent-based model to study the interactions between innate and adaptive immunity Three-dimensional modeling of angiogenesis in porous biomaterial scaffolds Discovering novel cancer therapies: A computational modeling and search approach Multiobjective Optimization Based-Approach for Discovering Novel Cancer Therapies Multi-scale Modeling and Game-Theoretic Analysis of Mitochondrial Process Elucidates the Hidden Mechanism of Warburg Effect in Tumorigenesis PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems PhysiBoSS: A multiscale agent-based modelling framework integrating physical dimension and cell signalling Active diffusion in oocytes nonspecifically centers large objects during prophase I and meiosis I Rapid community-driven development of a SARS-CoV-2 tissue simulator TISON: a nextgeneration multi-scale modeling theatre for in silico systems oncology 6th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation-The CHIC Project Workshop (IARWISOCI) 5th International Advanced Research Workshop on In Silico Oncology and Cancer Investigation-The TUMOR Project Workshop (IARWISOCI) ACGT: advancing clinico-genomic trials on cancer-four years of experience Clinically Oriented Translational Cancer Multilevel Modeling: The ContraCancrum Project p-Medicine: From data sharing and integration via VPH models to personalized medicine The TUMOR project: Integrating cancer model repositories for supporting predictive oncology Collaborative Open Plant Omics-einfrastructure for plant sciences View project PhenoMeNal-Large Scale Computing for Medical Metabolomics View project SEE PROFILE Computational horizons in cancer (CHIC): Developing meta-and hyper-multiscale models and repositories for in Silico Oncology -A brief technical outline of the project Web-Service Based Analysis of Geneexpression Data for Cancer Patients. This Vol is Dedic to cancer patients Building a system for advancing clinico-genomic trials on cancer The ACGT Oncosimulator: from conceptualization to development via multiscale cancer modeling. This Vol is Dedic to cancer patients Translating multiscale cancer models into clinical trials: Simulating breast cancer tumor dynamics within the framework of the "Trial of Principle" clinical trial and the ACGT project Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Multilevel cancer modeling in the clinical environment: Simulating the behavior of Wilms tumor in the context of the SIOP 2001/GPOH clinical trial and the ACGT project In silico'oncology for clinical decision making in the context of nephroblastoma IMENSE: An einfrastructure environment for patient specific multiscale data integration, modelling and clinical treatment Clinically driven design of multi-scale cancer models: the ContraCancrum project paradigm. Interface Focus An Explicit Boundary Condition Treatment of a Diffusion-Based Glioblastoma Tumor Growth Model. This Vol is Dedic to cancer patients In Silico Oncology: A Hypermatrix-Operator Formulation of a Top-Down Multiscale Simulation Model of Tumor Response to Treatment Integrating Multiscale Modeling with Drug Effects for Cancer Treatment Exploiting Clinical Trial Data Drastically Narrows the Window of Possible Solutions to the Problem of Clinical Adaptation of a Multiscale Cancer Model Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs Application of ANOVA-Based Global Sensitivity Analysis to a Multiscale Cancer Model. This Vol is Dedic to cancer patients Approximating the diffusion-reaction equation for developing glioma models for the ContraCancrum Project: a showcase. This Vol is Dedic to cancer patients Molecular Personalization of Cancer Treatment via a Multiscale Simulation Model of Tumor Response to Therapy. The Paradigm of Glioblastoma Treated with Temozolomide. This Vol is Dedic to cancer patients The p-medicine portal-a collaboration platform for research in personalised medicine Towards in silico oncology: adapting a four dimensional nephroblastoma treatment model to a clinical trial case based on multi-method sensitivity analysis Development of the p-medicine oncosimulator as a parallel treatment support system Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data The technologically integrated oncosimulator: Combining multiscale cancer modeling with information technology in the in silico oncology context Towards patient personalization of an Acute Lymphoblastic Leukemia Model during the oral administration of prednisone in children: Initiating the ALL Oncosimulator In Silico Oncology : Developing and Clinically Adapting the Acute Lymphoblastic Leukemia ( ALL ) Oncosimulator by Exploiting Pathway Based Gene Expression Analysis in the Context of t A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulator Workflowdriven clinical decision support for personalized oncology Advancing cancer systems biology: Introducing the Center for the Development of a Virtual Tumor E-CELL: Software environment for whole cell simulation A short introduction to CellML FieldML: concepts and implementation Concept and requirements of an in silico cancer modelling markup language Simulating non-small cell lung cancer with a multiscale agent-based model Connecting digital cancer model repositories with markup: introducing TumorML version 1.0 Web-Based Workflow Planning Platform Supporting the Design and Execution of Complex Multiscale Cancer Models Simulating the impact of a molecular 'decisionprocess' on cellular phenotype and multicellular patterns in brain tumors Genome-Scale Metabolic Modeling Elucidates the Role of Proliferative Adaptation in Causing the Warburg Effect In silico oncology: exploiting clinical studies to clinically adapt and validate multiscale oncosimulators In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model In Silico Neuro-Oncology: Brownian Motion-Based Mathematical Treatment as a Potential Platform for Modeling the Infiltration of Glioma Cells into Normal Brain Tissue Differentiation resistance through altered retinoblastoma protein function in acute lymphoblastic leukemia: in silico modeling of the deregulations in the G1/S restriction point pathway A numerical handling of the boundary conditions imposed by the skull on an inhomogeneous diffusion-reaction model of glioblastoma invasion into the brain: Clinical validation aspects Computational horizons in cancer (chic) The Genotype-Tissue Expression (GTEx) project The Cancer Genome Atlas Clinical Explorer: A web and mobile interface for identifying clinical-genomic driver associations A practical guide to The Cancer Genome Atlas (TCGA) MERAV: A tool for comparing gene expression across human tissues and cell types The NCI Genomic Data Commons as an engine for precision medicine TCPA: A resource for cancer functional 60 The Human Protein Atlas-a tool for pathology